TeraRecon Applauded by Frost & Sullivan for Solving Time-related Challenges in Neurological Care and Its Market-leading Position

TeraRecon partners with different vendors to provide precise, AI-supported patient care and expand in the neurological solutions market and other disease areas, improving patient outcomes. SAN ANTONIO, Sept. 7, 2023 /PRNewswire/ -- Recently, Frost & Sullivan researched the AI-based neurological solutions industry and, based on its analysis, recognizes TeraRecon, a ConcertAI company, with the 2023 Global Company of the Year Award. The US-based company operates in more than 74 countries and offers AI-empowered solutions for radiology, oncology, cardiology, vascular surgery, and neurology. It has 5,376 active installations, more than 53,000 active clinical users, and more than 1,200 global customers. Over 1,900 health sites trust TeraRecon's solutions, demonstrating its brand equity. TeraRecon has ample industry experience as it first entered the imaging industry and transitioned into advanced imaging and AI-based solutions based on customer needs. TeraRecon embodies the leadership focus criterion by offering products that may aid physicians with applications including stroke, brain tumors, multiple sclerosis, dementia, Alzheimer's disease, epilepsy, and other neurovascular conditions. 2023 Global AI-based Neurological Solutions Company of the Year Award TeraRecon offers Intuition, an advanced visualization imaging solution; Eureka Clinical AI, an AI-based platform for coordinated care; and TR Neuro and Neuro Suite, AI-based solutions for neurovascular conditions. Its vendor-neutral solutions provide simplified workflows and actionable insights. TeraRecon's Neuro Suite isan exhaustive and advanced AI-driven clinical suite, purpose-built for providing the physician with insights, and care activation in many neurological condition states. The solutions aid in neuroimaging analysis and physician made treatment decisions. TR Neuro solves time-related challenges in neurological care, rapidly detecting LVO and ICH and reducing door-to-care time. Utkarsha Soundankar, senior research analyst at Frost & Sullivan, observed, "TeraRecon's workflow-driven and clinician-centric solutions ensure increased productivity, consistency, reproducibility, and easy result communication, and it offers dedicated tools for neurological conditions." TR Neuro provides detection and patient care activation in neurovascular emergencies and increases the readiness of neurological emergency care centers. The clinical workflow solution connects the care team workflow, maintains standardization across the care continuum, and provides timely and coordinated care in neurological settings to support collaborative care. The Eureka Clinical AI platform enables care teams in various specialties to see results, confirm findings, and receive mobile alerts, thereby providing timely patient care. With its advanced AI-based secure solutions, TeraRecon continuously meets customer needs and improves patient outcomes. It demonstrates high growth potential and is well-positioned to improve the AI-based neurological solutions industry. "TeraRecon's advanced AI-based solutions assist in the rapid management and care of neurovascular patients. The clinician-friendly solutions provide on-the-go view options and aid the clinician in decision making to solve challenges across the care continuum and provide advanced patient care, improved patient outcomes, and a reduced financial burden of managing neurological conditions," added Soundankar.